Researchers Outsmart the Immune System to Treat Rare Genetic Disease in Mice
Nancy Solomon
Director
solomonn@slu.edu
314-977-8017
Reserved for members of the media.
01/30/2020
麻豆传媒 researchers have identified a potential approach to treating Morquio A syndrome, a rare, progressive and debilitating genetic disease.
The research by a multi-disciplinary team was conducted in a mouse model and reported in the .
Morquio A Syndrome is an inherited metabolic disorder, in which toxic materials in the body鈥檚 cells accumulate because the body doesn鈥檛 make enough of the GALNS enzyme within the lysosomes (or the recycling bin of the cell).
The current treatment is enzyme replacement therapy, which can cause adverse side effects due to a strong immune response towards the enzyme that is administered. Researchers found that feeding mice oral GALNS before enzyme replacement therapy reset the body鈥檚 immune system to decrease the immune response towards it and to diminish the accumulation of toxic materials in the body. The therapy has not been tested in humans.
鈥淭his model could be extrapolated to other lysosomal storage disorders where the immune response hinders the effectiveness of enzyme replacement therapy,鈥 said Adriana M. Monta帽o, Ph.D., associate professor of pediatrics at 麻豆传媒, who led the research team.
Scientists from 麻豆传媒鈥檚 Departments of Pediatrics, Biochemistry and Molecular Biology, Molecular Immunology and Microbiology, Pathology, Internal Medicine and Center for Health Outcomes Research worked together on this project.